•   
  •   

Australia South Australian coronavirus vaccine candidate shows positive results in phase one human trials

09:26  01 august  2020
09:26  01 august  2020 Source:   abc.net.au

South Australian coronavirus vaccine candidate shows positive results in phase one human trials

  South Australian coronavirus vaccine candidate shows positive results in phase one human trials Members of a Melbourne-based criminal syndicate have been charged for conspiring to import $80 million worth of cocaine into Australia.

COVAX-19 is also one of only a handful of potential vaccines that have progressed beyond phase one of human trials in the world, which one expert called exciting. “Safety data from the clinical trials shows the vaccine isn’t showing any problems at all and is inducing the right type of immune

Currently, four coronavirus vaccine candidates are in Phase III human trials , out of which Oxford University is aiming to wrap up the trials of its AstraZeneca's vaccine is being widely considered the leading candidate after results from early-stage human trials showed it was safe and produced

a person standing in a room: COVAX-19 has shown positive results during phase one human trials in Adelaide. (ABC News) © Provided by ABC Health COVAX-19 has shown positive results during phase one human trials in Adelaide. (ABC News)

Victorian aged care residents could be included in the next stage of testing for a potential COVID-19 vaccine that has shown positive results during phase one human trials in Adelaide.

The vaccine candidate, COVAX-19, was developed by Adelaide-based company Vaxine, which has laboratories at Flinders University.

Volunteers between the ages of 18 and 65 in Adelaide have been injected with two doses of either COVAX-19 or a placebo in the phase one trial.

Moderna's COVID-19 vaccine candidate moves into late-stage trial

  Moderna's COVID-19 vaccine candidate moves into late-stage trial Moderna's COVID-19 vaccine candidate moves into late-stage trialThe federal government is supporting Moderna's vaccine project with nearly a billion dollars and has chosen it as one of the first to enter large-scale human trials.

Depending on those results , J&J plans to start large-scale, phase 3 testing with a single-shot J&J's vaccine uses a common cold virus known as adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in "This study shows that even just a single immunization with the Ad26 vaccine leads to

Coronavirus vaccine made by Australian researchers passes first trial . Moderna Phase 1 results show coronavirus vaccine safe, induces Human trial for coronavirus vaccine starts in Queensland on 120 volunteers - and if successful it could be rolled out within months.

One of the volunteers for the phase one Adelaide trial was SA Best MP Frank Pangallo.

"I feel great — I had my second dose of the vaccine today and no side-effects for me," Mr Pangallo said on Friday.

"I'm really buoyed by the positive results."

Lead researcher Professor Nikolai Petrovsky said the vaccine candidate had been shown to be safe and to induce antibodies that attack the coronavirus that causes COVID-19.

"We've had no major side-effects in any of the subjects," said Professor Petrovsky.

He said the vaccine had also shown positive results in trials on animals in the United States in protecting them from COVID-19 infection.

"That makes us more confident that this is actually going to work and that we might have a successful vaccine on our hands," he said.

Coronavirus update: India trialling potential vaccine, cases in Africa pass 800,000

  Coronavirus update: India trialling potential vaccine, cases in Africa pass 800,000 India records 49,000 new coronavirus infections as the country begins its first human trials of a potential vaccine. In Africa, the number of cases passes 800,000.In Africa, the virus is spreading quickly, with South Africa so far its worst-hit nation, with more than half the continent's total caseload.

Early results from a phase 1 trial showed the vaccine was safe and prompted an immune response in humans . A COVID-19 vaccine candidate has shown it can prompt an immune response in the human The drug is now being tested in larger studies. Full coverage of the coronavirus outbreak.

Johnson & Johnson (JNJ) initiated first -in- human safety trials of its COVID-19 vaccine candidate after a single dose in pre-clinical studies showed “robust protection”.The pre-clinical study data disclosed that J&J’s investigational vector-based vaccine triggered a robust immune response and

If the vaccine candidate passes subsequent trials, it could be ready by year's end, he said.

"We can now test the vaccine in nursing home patients and show that it's effective in inducing the right type of immune responses and hopefully, ultimately, show that it's effective in preventing them getting infected," Professor Petrovsky said.

"Based on the safety of the vaccine in that [phase one] group, we're now actually going into the elderly, which is very relevant given the problems we're seeing in Victoria."

Vaccine trials coming to aged care homes

The developers of the vaccine are offering their trial to Victorian aged care facilities, where COVID-19 has taken a devastating toll, among other facilities.

"Under our existing approval for our trials, there's no reason those trials can't be extended to Victoria," Professor Petrovsky said.

"We would just need to identify sites in Victoria that wanted to be part of the trial."

Potential COVID-19 vaccine passes phase one of clinical trials

  Potential COVID-19 vaccine passes phase one of clinical trials Australia could be the first country to develop a COVID-19 vaccine, but it could be rolled out in Cananda first because the government has invested in University of Queensland according to Flinders' University Professor Nikolai Petrovsky. “Everything is on track, we have now proof that the vaccine is protecting against the virus in relevant animal models," Mr Petrovsky told Sky News.

Australian biotechnology company Vaxine Pty Ltd expects to start Phase II trials of its potential COVID-19 vaccine in the next few weeks after " positive " results from the first stage human study No vaccine has yet been approved for COVID-19, the disease caused by the new coronavirus that

Recent vaccine news. Preliminary results from a combined phase 1 /2 trial show that the University In phase 2, the vaccine is given to hundreds of people so scientists can learn more about its safety American biotech company Moderna is developing a vaccine candidate using messenger RNA (or

There have been 94 outbreaks of the coronavirus that causes COVID-19 in Victorian aged care homes, linked to 61 deaths.

Those who have recovered from COVID-19 are also candidates for the phase two trial — which will also aim to test whether the drug might help prevent reinfection.

If the vaccine candidate also passes phase two, the final phase would involve testing on a large population with a high incidence of COVID-19 transmission overseas.

From there, Professor Petrovsky said, it would require approval from the Therapeutic Goods Administration before becoming available for distribution in Australia.

[Hearken embed]

Gallery: How to identify the warning signs of a stroke (StarsInsider)

a man lying on a bed: Did you know that strokes are the second leading cause of death and the third leading cause of disability in the world? The information comes from a report by the World Health Organization (WHO). But how can you identify the symptoms of a stroke, which can easily be confused with other diseases? We have listed some warning signs that you should look out for. Click to find out more.

Global recovery will come faster if COVID vaccine available to all - WHO chief .
Global recovery will come faster if COVID vaccine available to all - WHO chiefHe was speaking in an online panel discussion with members of the Aspen Security Forum in the United States moderated by the NBC network.

—   Share news in the SOC. Networks
usr: 2
This is interesting!